219 related articles for article (PubMed ID: 35522916)
1. Introducing Checkpoint Inhibitors Into the Curative Setting of Head and Neck Cancers: Lessons Learned, Future Considerations.
Nenclares P; Rullan A; Tam K; Dunn LA; St John M; Harrington KJ
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-16. PubMed ID: 35522916
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant immunotherapy for head and neck squamous cell carcinoma.
Kürten CHL; Ferris RL
Laryngorhinootologie; 2024 May; 103(S 01):S167-S187. PubMed ID: 38697147
[TBL] [Abstract][Full Text] [Related]
3. Advancements in neoadjuvant immune checkpoint inhibitor therapy for locally advanced head and neck squamous Carcinoma: A narrative review.
Li J; Luo Z; Jiang S; Li J
Int Immunopharmacol; 2024 Jun; 134():112200. PubMed ID: 38744175
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus.
Wang H; Zhao Q; Zhang Y; Zhang Q; Zheng Z; Liu S; Liu Z; Meng L; Xin Y; Jiang X
Front Immunol; 2021; 12():652054. PubMed ID: 34305889
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
Leidner R; Crittenden M; Young K; Xiao H; Wu Y; Couey MA; Patel AA; Cheng AC; Watters AL; Bifulco C; Morris G; Rushforth L; Nemeth S; Urba WJ; Gough M; Bell RB
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963014
[TBL] [Abstract][Full Text] [Related]
6. A systematic review of neoadjuvant and definitive immunotherapy in locally advanced head and neck squamous cell carcinoma.
Nindra U; Hurwitz J; Forstner D; Chin V; Gallagher R; Liu J
Cancer Med; 2023 May; 12(10):11234-11247. PubMed ID: 36934434
[TBL] [Abstract][Full Text] [Related]
7. [Immunotherapy for head and neck squamous cell carcinoma].
Lecocq M; Poncin A; Sautois B
Rev Med Liege; 2021 May; 76(5-6):398-402. PubMed ID: 34080370
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for head and neck squamous cell carcinoma: current status and perspectives.
Daste A; Larroquette M; Gibson N; Lasserre M; Domblides C
Immunotherapy; 2024 Feb; 16(3):187-197. PubMed ID: 38126161
[TBL] [Abstract][Full Text] [Related]
9. The Use of Immune Regulation in Treating Head and Neck Squamous Cell Carcinoma (HNSCC).
Wang CW; Biswas PK; Islam A; Chen MK; Chueh PJ
Cells; 2024 Feb; 13(5):. PubMed ID: 38474377
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Approaches With Immune Checkpoint Inhibitors in Head and Neck Cancers and the Role of PD-L1 as a Biomarker.
Oualla K; Castelo Branco L; Nouiyakh L; Amaadour L; Benbrahim Z; Arifi S; Mellas N
Cancer Control; 2021; 28():10732748211004878. PubMed ID: 33827280
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
Łasińska I; Kolenda T; Teresiak A; Lamperska KM; Galus Ł; Mackiewicz J
Anticancer Agents Med Chem; 2019; 19(3):290-303. PubMed ID: 30198439
[TBL] [Abstract][Full Text] [Related]
12. Current landscape of immunotherapy trials in locally advanced and high-risk head and neck cancer.
Park R; Park JC
Immunotherapy; 2021 Aug; 13(11):931-940. PubMed ID: 34100301
[TBL] [Abstract][Full Text] [Related]
13. Treatment Response of Gingival Squamous-Cell Carcinoma to Palliative Intent Immunotherapy.
Trehan N; Debbas A; Sternick M; Johnson J; Gates JC
Curr Oncol; 2023 Dec; 30(12):10519-10529. PubMed ID: 38132401
[TBL] [Abstract][Full Text] [Related]
14. Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update.
Bhatia A; Burtness B
Drugs; 2023 Feb; 83(3):217-248. PubMed ID: 36645621
[TBL] [Abstract][Full Text] [Related]
15. Revisiting the concept of neoadjuvant and induction therapy in head and neck cancer with the advent of immunotherapy.
Smussi D; Mattavelli D; Paderno A; Gurizzan C; Lorini L; Romani C; Bignotti E; Grammatica A; Ravanelli M; Bossi P
Cancer Treat Rev; 2023 Dec; 121():102644. PubMed ID: 37862833
[TBL] [Abstract][Full Text] [Related]
16. How Should We Approach Locally Advanced Squamous Cell Carcinoma of Head and Neck Cancer Patients Ineligible for Standard Non-surgical Treatment?
Yokota T; Hamauchi S; Shirasu H; Onozawa Y; Ogawa H; Onoe T; Onitsuka T
Curr Oncol Rep; 2020 Sep; 22(12):118. PubMed ID: 32945988
[TBL] [Abstract][Full Text] [Related]
17. Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma.
Zech HB; Moeckelmann N; Boettcher A; Muenscher A; Binder M; Vettorazzi E; Bokemeyer C; Schafhausen P; Betz CS; Busch CJ
Future Oncol; 2020 Dec; 16(36):3035-3043. PubMed ID: 32902312
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
Poulose JV; Kainickal CT
World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
[TBL] [Abstract][Full Text] [Related]
19. Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches.
Vathiotis IA; Johnson JM; Luginbuhl A; Cognetti D; Curry J; Argiris A
Cancer Treat Rev; 2022 Sep; 109():102437. PubMed ID: 35868194
[TBL] [Abstract][Full Text] [Related]
20. Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma.
Hanna GJ; Adkins DR; Zolkind P; Uppaluri R
Oral Oncol; 2017 Oct; 73():65-69. PubMed ID: 28939078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
